Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via
intravenous drip infusion once a day in the patients with ALS based on the changes in the
revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in
double-blind, placebo-controlled manner. The study is also to examine the safety of MCI-186
to the ALS patients.